Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

Abstract A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia (AML) may be improved by a liposomal encapsulation of cytarabine and daunorubicin (CPX‐351). This phase 3 study represents a unique example of prospective data in this rare subgroup providing...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sarah Bertoli, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Eric Delabesse, Thibault Comont, Audrey Sarry, Françoise Huguet, Emilie Bérard, Christian Récher
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2019-07-01
coleção:	Cancer Medicine
Assuntos:	acute myeloid leukemia azacitidine CPX‐351 intensive chemotherapy myelodysplasia‐related changes secondary AML
Acesso em linha:	https://doi.org/10.1002/cam4.2020
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!